Advertisement

Evaluation of Peptic Ulcer Disease

  • Thomas C. Tsai
  • David C. BrooksEmail author
Chapter

Abstract

Peptic ulcers are defects in the gastric or duodenal mucosa through the muscularis mucosa. Unlike erosions or gastritis which are small or superficial lesions that involve only the mucosa, peptic ulcers can vary from as small as 5 mm to several centimeters, and the depth of injury may lead to life-threatening complications such as GI bleeding, perforation, or gastric outlet obstruction. Traditionally, peptic ulcer disease was thought to be secondary to acid hypersecretion. However, recent evidence suggests that the pathogenesis of peptic ulcers is multifactorial and due to an imbalance of inciting factors and protective factors. A robust literature has shown that eradication of H. pylori can reduce the rate of ulcer recurrence. Additionally, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin have also been closely linked to the formation of peptic ulcers due to the inhibition of cyclooxygenase-1 (COX-1) which results in impaired mucosal healing. Evaluation of peptic ulcer disease now largely rests on the diagnosis of these two predisposing factors of H. pylori infection and impaired mucosal healing from NSAID use.

Keywords

Peptic ulcer disease Peptic ulcers H. pylori Nonsteroidal anti-inflammatory drugs NSAID 

References

  1. 1.
    Lanas A, Chan FK. Peptic ulcer disease. Lancet. 2017;390(10094):613–24.CrossRefGoogle Scholar
  2. 2.
    Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500–11.CrossRefGoogle Scholar
  3. 3.
    Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther. 2009;29:938–46.CrossRefGoogle Scholar
  4. 4.
    Wang YR, Richter JE, Dempsey DT. Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006. Ann Surg. 2010;251:51–8.CrossRefGoogle Scholar
  5. 5.
    Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther. 1995;9(Suppl 2):59–69.PubMedGoogle Scholar
  6. 6.
    Sipponen P, Varis K, Fraki O, Korri UM, Seppala K, Siurala M. Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients. Scand J Gastroenterol. 1990;25:966–73.CrossRefGoogle Scholar
  7. 7.
    Charpignon C, Lesgourgues B, Pariente A, et al. Peptic ulcer disease: one in five is related to neither Helicobacter pylori nor aspirin/NSAID intake. Aliment Pharmacol Ther. 2013;38:946–54.CrossRefGoogle Scholar
  8. 8.
    Crooks CJ, West J, Card TR. Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology. 2013;144:1384–93. 93 e1–2; quiz e18–9.CrossRefGoogle Scholar
  9. 9.
    Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology. 2009;136:1863–73.CrossRefGoogle Scholar
  10. 10.
    Yamaoka Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol. 2010;7:629–41.CrossRefGoogle Scholar
  11. 11.
    Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. Am J Gastroenterol. 2006;101:848–63.CrossRefGoogle Scholar
  12. 12.
    Lanas A, Carrera-Lasfuentes P, Arguedas Y, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2015;13:906–12. e2.CrossRefGoogle Scholar
  13. 13.
    Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55:1731–8.CrossRefGoogle Scholar
  14. 14.
    Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14–22.CrossRefGoogle Scholar
  15. 15.
    Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002;359:9–13.CrossRefGoogle Scholar
  16. 16.
    Labenz J, Blum AL, Bolten WW, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut. 2002;51:329–35.CrossRefGoogle Scholar
  17. 17.
    Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007;369:1621–6.CrossRefGoogle Scholar
  18. 18.
    Johnson HD. Gastric ulcer: classification, blood group characteristics, secretion patterns and pathogenesis. Ann Surg. 1965;162:996–1004.CrossRefGoogle Scholar
  19. 19.
    Scott JW, Olufajo OA, Brat GA, et al. Use of national burden to define operative emergency general surgery. JAMA Surg. 2016;151:e160480.CrossRefGoogle Scholar
  20. 20.
    Sarosi GA Jr, Jaiswal KR, Nwariaku FE, Asolati M, Fleming JB, Anthony T. Surgical therapy of peptic ulcers in the 21st century: more common than you think. Am J Surg. 2005;190:775–9.CrossRefGoogle Scholar
  21. 21.
    Agreus L, Talley NJ, Jones M. Value of the “Test & Treat” strategy for uninvestigated dyspepsia at low prevalence rates of Helicobacter pylori in the population. Helicobacter. 2016;21:186–91.CrossRefGoogle Scholar
  22. 22.
    Delaney BC, Qume M, Moayyedi P, et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ. 2008;336:651–4.CrossRefGoogle Scholar
  23. 23.
    Gisbert JP, Esteban C, Jimenez I, Moreno-Otero R. 13C-urea breath test during hospitalization for the diagnosis of Helicobacter pylori infection in peptic ulcer bleeding. Helicobacter. 2007;12:231–7.CrossRefGoogle Scholar
  24. 24.
    Lin HJ, Lo WC, Perng CL, et al. Helicobacter pylori stool antigen test in patients with bleeding peptic ulcers. Helicobacter. 2004;9:663–8.CrossRefGoogle Scholar
  25. 25.
    Laine L. Upper gastrointestinal bleeding due to a peptic ulcer. N Engl J Med. 2016;375:1198.CrossRefGoogle Scholar
  26. 26.
    Dooley CP, Larson AW, Stace NH, et al. Double-contrast barium meal and upper gastrointestinal endoscopy. A comparative study. Ann Intern Med. 1984;101:538–45.CrossRefGoogle Scholar
  27. 27.
    Glick SN. Duodenal ulcer. Radiol Clin N Am. 1994;32:1259–74.PubMedGoogle Scholar
  28. 28.
    Greenberger NJ, Blumber RS, Burakoff R. Current diagnosis and treatment: gastroenterology, hepatology, & endoscopy. 3rd ed. New York: McGraw-Hill Education; 2016.Google Scholar

Copyright information

© SAGES 2019

Authors and Affiliations

  1. 1.Department of SurgeryBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA
  2. 2.Division of General and Gastrointestinal SurgeryBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations